Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Q2 2019 Y-mAbs Therapeutics, Inc Earnings Call Transcript

Aug 14, 2019 / 08:30PM GMT
Release Date Price: $26.16 (+1.32%)
Operator

Greetings and welcome to the Y-mAbs Therapeutics Inc. second-quarter 2019 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mr. Thomas Gad, Chairman and President of Y-mAbs. Thank you, Mr. Gad. You may begin.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Chairman, President, and Head of Business Development and Strategy

Thank you, Terry. Hello, everyone, and thank you for dialing into our second-quarter earnings call. Today we will hear remarks from our Chief Executive Officer, Dr. Claus Moller, and our Chief Financial Officer, Bo Kruse.

Overall, we are very pleased with our second-quarter results. Our reported spending of $27.5 million year to date is really a direct result of our highly dedicated and productive team effort to prepare Y-mAbs to be ready to submit two BLAs in 2019.

We ended the quarter with $120 million in cash. And taking into consideration our potential approval timelines of Q3 2020 for naxitamab and omburtamab, and also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot